An estimated 320,000 women in the U.S. will be diagnosed with invasive breast cancer in 2026, and about 330,000 men will be diagnosed with prostate cancer.¹ For health systems, that means sustained demand across screening, diagnosis, and follow-up, with imaging playing a central role in identifying disease and informing what happens next.
Breast and prostate imaging also require a high degree of clinical expertise. Subtle findings can be difficult to detect, interpretation can vary between readers, and tasks such as density assessment, segmentation, measurement and structured scoring add time and complexity.
AI can help address those challenges, but as health systems expand their use of clinical AI, the question evolves from “which algorithm to adopt?” to “how to add specialized capabilities without creating another disconnected application, infrastructure layer or governance process?”
DeepHealth’s AI-powered breast and prostate imaging solutions are now available through the Rapid Enterprise™ Platform, expanding the specialized clinical AI health systems can access through a connected enterprise environment.
The integration brings DeepHealth’s mammography and prostate MRI capabilities alongside clinical AI in other disease states, radiology workflows, care coordination, and patient management available through RapidAI.
DeepHealth solutions include:
Mammo Dx detects and localizes regions of interest for masses, architectural distortions, asymmetries, microcalcifications, degree of suspicion, and arterial calcifications. It rates the degree of suspicion at the case level for worklist prioritization and at the lesion level as an AI confidence score. It also includes density assessment, automatically assigning BI-RADS 5th edition density categories on 2D or 3D mammograms to reduce inter-reader variability without adding workflow steps, and it synchronizes priors and compares risk scores across exams and systems.
Mammo Dx detects more than 10% more cancers¹ and delivers an approximately 11% relative increase in cancer detection in Black women.¹ Its AI, trained on more than 300,000 studies, delivers superior accuracy, and in a group of general radiologists it supported specialist-level care and better diagnostic performance.¹˒²
Breast Arterial Calcification (BAC) Assessment automatically flags breast arterial calcifications on standard 2D and 3D screening mammograms, with a standardized scorecard view and slice-level visualization. In FDA clinical performance testing, it showed sensitivity of more than 90% and specificity of more than 80%.⁵ Maryland now requires patient notification when BAC is found on mammograms (HB 1364),² making consistent detection a practical consideration for screening programs.
Prostate MR provides AI-powered detection and classification of suspicious lesions, with automated prostate gland segmentation. It contours the gland and lesion candidates with volume measurements readers can refine as needed, calculates PSA density from gland volume, scores risk per lesion and pre-populates sector maps for structured PI-RADS reporting. In a multi-reader study, it delivered a 27% increase in lesion detection, a 65% reduction in segmentation variability among radiologists and a 15% relative improvement in reader detection performance.⁶
Specialized AI can deliver meaningful clinical value, but adding each capability as a standalone solution can also create more integrations, infrastructure, and oversight for health systems to manage.
The Rapid Enterprise Platform provides a way to bring DeepHealth’s breast and prostate imaging AI into the same environment as other native and partner AI capabilities, with shared infrastructure, centralized governance, and visibility into performance.
That gives health systems a more scalable way to expand AI based on clinical need without treating every new capability as a separate technology project.
It also extends the value of AI beyond the initial finding. Because RapidAI connects radiology AI with care coordination and patient management, insights can help inform the clinicians and workflows responsible for follow-up, treatment, and ongoing patient care.
DeepHealth’s breast and prostate imaging solutions expand the growing portfolio of native and partner AI available through the Rapid Enterprise Platform. The goal is not simply to offer more algorithms, but to give health systems a more connected way to adopt the clinical AI their teams need as technology evolves.
The integration includes DeepHealth's Mammo DX solution, Breast Arterial Calcification Assessment and Prostate MR solutions.
It detects and localizes regions of interest on mammograms, rates the suspicion of cancer at the case and lesion level, provides a density score and compares current exams with priors.
It automatically flags breast arterial calcifications on screening mammograms and presents them in a standardized scorecard view with slice-level visualization.
It automatically segments the prostate gland, detects and risk-scores lesion candidates, calculates PSA density and pre-populates sector maps for structured PI-RADS reporting.
Accessing DeepHealth’s breast and prostate imaging AI through the Rapid Enterprise Platform allows health systems to deploy specialized clinical AI alongside other AI capabilities rather than managing it as a separate point solution. Shared infrastructure, centralized AI governance and connected clinical workflows support a more scalable approach to enterprise AI adoption.
The Rapid Enterprise Platform connects clinical AI with radiology workflows, care coordination and patient management, helping health systems support both the interpretation of findings and the clinical workflows that follow.
1 Kim et al. “Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists.” Radiology Artificial Intelligence. Mar 2024.
2 McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025.
³ Louis LD, et al. Nat Health. 2026;1:58–66.
⁴ Conant EF, et al. Radiol Artif Intell. 2019;1(4):e180096.
⁵ FDA 510(k) clearance K254131, Clinical Performance Testing.
6 Brittaney Everitt , Valerio Fortunati, Jiye Kim, Jim Tol, Abigail Ko, Guus Kolpa, Felix Leufkens, Bryan Haslam, Impact of an integrated AI platform on prostate MRI interpretation: a multi-reader study, ECR Conference Presentation, 2026.
1046-MKT-Web-1126